Pertussis vaccination for adolescents and adults

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1669-1676

  Franco, Elisabetta ^a   Giambi, Cristina ^a   Ialacci, Rita ^a   Maurici, Massimo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adult pertussis infection; Booster dose; Pertussis vaccination

Indexed keywords

ACELLULAR VACCINE; ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; FIMBRIA PROTEIN; HEMAGGLUTININ; HEPATITIS B VACCINE; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; ADULT DISEASE; AGE; AGING; APNEA; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT EXAMINATION; COUGHING; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HEALTH PROGRAM; HERD IMMUNITY; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNOGENICITY; INCIDENCE; MASS IMMUNIZATION; MOLECULAR EVOLUTION; PERTUSSIS; PNEUMONIA; POLYMERASE CHAIN REACTION; PREVALENCE; PUBLIC HEALTH; REVIEW; SYMPTOM; TREATMENT INDICATION; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIGENIC VARIATION; BORDETELLA PERTUSSIS; CHILD; CHILD DAY CARE CENTERS; CHILD, PRESCHOOL; CONTACT TRACING; DISEASE OUTBREAKS; DISEASE SUSCEPTIBILITY; DISEASE TRANSMISSION, HORIZONTAL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; PERTUSSIS VACCINE; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; SCHOOLS; VACCINATION; VACCINES, ACELLULAR; WHOOPING COUGH;

BACTERIA (MICROORGANISMS); BORDETELLA; BORDETELLA PERTUSSIS;

EID: 5644277616     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1669     Document Type: Review

References (69)

1. HEININGER U: Pertussis: an old disease that is still with us. Curr. Opin. Infect. Dis. (2001) 14(3):329-333.
2. CAMPINS-MARTI M, MORAGA-LLOP FA: Acellular pertussis vaccines for use among infants and young children. Expert Opin. Pharmacother. (2004) 5(4):807-817. A comprehensive review concerning the efficacy, immunogenicity and safety of aP vaccine and its use in childhood.
3. WORLD HEALTH ORGANIZATION: Pertussis vaccines - WHO position paper. Wkly Epidemiol. Rec. (1999) 74:137-144. World Health Organization position paper on the use of pertussis vaccines in the global context.
4. YEH SH: Pertussis: persistent pathogen, imperfect vaccines. Expert Rev. Vaccines (2003) 2(1):113-127.
5. WORLD HEALTH ORGANIZATION, REGIONAL OFFICE FOR EUROPE: Strategy for pertussis prevention in the World Health Organization's European Region. J. Infect. Dis. (1996) 174(Suppl. 3):S291-S294.
6. KEITEL WA: Cellular and acellular pertussis vaccines in adults. Clin. Infect. Dis. (1999) 28(Suppl. 2):S118-S13.
7. KEITEL WA, MUENZ LR, DECKER MD et al.: A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J. Infect. Dis. (1999) 180:397-403.
8. ROTHSTEIN EP, ANDERSON EL, DECKER MD et al.: An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates. Vaccine (1999) 17:2999-3006.
9. MINH NN, HE Q, RAMALHO A et al.: Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics (1999) 104(6):e70.
10. HALPERIN SA, SMITH B, RUSSELL M et al.: An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 18(4):1312-1319.
11. HALPERIN SA, SMITH B, RUSSELL M et al.: Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr. Infect. Dis. J. (2000) 19(4):276-283.
12. VAN DAMME P, BURGESS M: Immunogenicity of a combined diphtheria-tetanus- acellular pertussis vaccine in adults. Vaccine (2004) 22:305-308.
13. GURIS D, STREBEL PM, BARDENHEIER B et al.: Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin. Infect. Dis. (1999) 28:1230-1237.
14. BLACK S: Epidemiology of pertussis. Pediatr. Infect. Dis. J. (1997) 16(4):S85-S89.
15. HETHCOTE HW, HORBY P, MCINTYRE P: Using computer simulation to compare pertussis vaccination strategies in Australia. Vaccine (2004) 22:2181-2191.
16. OLIN P, GUSTAFSSON L, BARRETO L et al.: Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine (2003) 21:2015-2021.
17. ORENSTEIN WA: Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin. Infect. Dis. (1999) 28(Suppl.2):S147-S150.
18. NO AUTHORS LISTED: Pertussis - United States, 1997-2000. CDC. MMWR Mort. Mortal. Wkly Rep. (2002) 51:73-76. CDC report summarising national surveillance data of pertussis in the US.
19. YIH WK, LETT SM, DES VIGNES FN, GARRISON KM, SIPE PL, MARCHANT CD: The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J. Infect. Dis. (2000) 182:1409-1416.
20. SKOWRONSKI D, DE SERRES G, MACDONALD D et al.: The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis. (2002) 185:1448-1453.
21. VAN BUYNDER PG, OWEN D, VURDIEN JE, ANDREWS NJ, MATTHEWS RC, MILLER E: Bordetella pertussis surveillance in England and Wales: 1995-97. Epidemiol. Infect. (1999) 123:403-411.
22. MCINTYRE P, AMIN J, GIDDING H et al.: Vaccine preventable disease and vaccination coverage in Australia, 1993-1998. Commun. Dis. Intell. (2000) (Suppl.):22-26.
23. BRENNAN M, STREBEL P, GEORGE H et al.: Evidence for transmission of pertussis in schools, Massachussets, 1996: epidemiologic data supported by pulsed field gel electroforesis studies. J. Infect. Dis (2000) 181:210-215.
24. SRUGO I, BENILEVI D, MADEB R, SHAPIRO S et al.: Pertussis infection fully vaccinated children in day-care centers, Israel. Emerg. Infect. Dis. (2000) 6(5):526-529.
25. CORDOVA SP, GILLES MT, BEERS MY: The outbreak that had to happen: Bordetella pertussis in North West Australia in 1999. Commun. Dis. Intell. (2000) 24:375-379.
26. NO AUTHORS LISTED: Pertussis outbreak among adults at an oil refinery-Illinois. MMWR Morb. Mortal. Wkly Rep. (2003) 52(1):1-4.
27. NO AUTHORS LISTED: Transmission of pertussis from adult to infant - Michigan 1993. MMWR Morb. Mortal. Wkly Rep. (1995) 44(4):74-76.
28. WIRSING VON KÖNIG CH, POSTELS-MULTANI S, BOCK HL, SCHMITT HJ: Pertussis in adults: frequency of transmission after household exposure. Lancet (1995) 346:1326-1329.
29. BARON S, NJAMKEPO E, GRIMPREL E et al.: Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr. Infect. Dis. J. (1998) 17(5):412-418.
30. ELLIOTT E, MCINTYRE P, RIDLEY G et al.: National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr. Infect. Dis. J. (2004) 23(3):246-252.
31. EVERETT S, HALLDORSON S, SAVOINI D et al.: School-associated pertussis outbreak - Yavapai County, Arizona, September 2002 - February 2003. MMWR Mort. Mortal. Wkly Rep. (2004) 53(10):216-219.
32. WIRSING VON KÖNIG CH, HALPERIN S, RIFFELMANN M, GUISI N: Pertussis of adults and infants. Lancet Infect. Dis. (2002) 2:744-750. An excellent review concerning pertussis epidemiology, clinical course and implications for vaccination strategies.
33. BIRKEBÆK NH, KRISTIANSEN M, SEEFELDT T et al.: Bordetella pertussis and chronic cough in adults. Clin. Infect. Dis. (1999) 29:1239-1242.
34. GILBERG S, NJAMKEPO E, PARENT DU CHÂTELET I et al.: Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J. Infect. Dis. (2002) 186:415-418.
35. JACKSON LA, CHERRY JD, WANG S, GRAYSTON JT: Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in University students with cough illnesses. Clin. Infect. Dis. (2000) 31:3-6.
36. CHERRY JD: Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin. Infect. Dis. (1999) 28(Suppl.2):S112-S117. Paper investigating various aspects of pertussis in adults, considering the possibility of a booster immunisation programme.
37. KONDA T, KAMACHI K, IWAKI M, MATSUNAGA Y: Distribution of pertussis antibodies among different age groups in Japan. Vaccine (2002) 20:1711-1717.
38. DOMÌNGUEZ A, VIDAL J, PLANS P, SALLERAS L: The seroepidemiology of B. pertussis infection in Catalonia, Spain. Epidemiol. Infect. (2001) 126:205-210.
39. GARCÌA-CORBEIRA P, DAL-RE R, AGUILAR L, GARCIA DE LOMAS J: Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross sectional study. Vaccine (2000) 18:2173-2176.
40. ROTA MC, AUSIELLO CM, D'AMELIO R et al.: Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clin. Infect. Dis. (1998) 26:297-302.
41. HEININGER U, KLICH K, STEHR K, CHERRY JD: Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics (1997) 100(6):e10.
42. YAARI E, YAFE-ZIMERMAN Y, SCHWARTZ SB et al.: Clinical manifestation of Bordetella pertussis infection in immunised children and young adults. Chest (1999) 115:1254-1258.
43. STORSAETER J, HALLANDER HO, GUSTAFSSON L, OLIN P: Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine (2003) 21:3542-3549.
44. SENZILET LD, HALPERIN SA, SPIKA JS et al.: Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin. Infect. Dis. (2001) 32:1691-1697.
45. NO AUTHORS LISTED: Pertussis deaths - United States, 2000. MMWR Morb. Mortal. Wkly Rep. (2002) 51(28):616-618.
46. GIL A, OYAGUEZ I, CARRASCO P, GONZALEZ A: Hospital admission for pertussis in Spain, 1995-1998. Vaccine (2001) 19:4791-4794.
47. MATTER HC: Pertussis surveillance in Switzerland, 1992 to 1997 - a large epidemic in 1994. What next? Euro Surveill. (1999) 4(12):130-133.
48. FUNG KS, YEUNG WL, WONG TW, SO KW, CHENG AF: Pertussis - a re-emerging infection? J. Infect. (2004) 48:145-148.
49. DE SERRES G, SHADMANI R, DUVAL B et al.: Morbidity of pertussis in adolescents and adults. J. Infect. Dis. (2000) 182:174-179. Study evaluating the effect of age on the clinical course of pertussis in adolescents and adults.
50. NO AUTHORS LISTED: Fatal case of unsuspected pertussis diagnosed from a blood culture - Minnesota, 2003. CDC. MMWR Morb. Mortal. Wkly Ref. (2004) 53(6):131-132.
51. NIELSEN NM, HEDEGAARD K, AABY P: Intensity of exposure and severity of whooping cough. J. Infect. (2001) 43:177-181.
52. BRUSS JB, SIBER GR: Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model. Infect. Immun. (2002) 70(8):4600-4608.
53. BRUSS JB, MALLEY R, HALPERIN S et al.: Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr. Infect. Dis. J. (1999) 18(6):505-511.
54. GRUBER MF: Maternal immunisation: US FDA regulatory considerations. Vaccine (2003) 21:3487-3491.
55. EDWARDS KM: Pertussis: an important target for maternal immunisation. Vaccine (2003) 21:3483-3486.
56. GARDNER P: Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal recommendations. Clin. Infect. Dis. (1999) 28(Suppl. 2):S131-S135.
57. CAMPINS-MARTÌ M, CHENG HK, FORSYTH K et al.: Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine (2001) 20:641-646. Paper considering the different immunisation strategies for older age groups.
58. D'ANGELO LJ, MAGNUS MD: The changing epidemiology of pertussis: should we adopt a vaccine policy for adolescents? J. Adolesc. Health. (2004) 34(2):119-120.
59. NO AUTHORS LISTED: National consensus conference on pertussis, Toronto, may 25-28, 2002. Can. Commun. Dis. Rep. (2003) 29(Suppl.3):1-33. State of the art on clinical, diagnostic, epidemiological and preventive aspects of B. pertussis infection.
60. HEWLETT EL, HALPERIN SA: Serological correlates of immunity to Bordetella pertussis. Vaccine (1998) 16(20):1899-1900.
61. TROLLFORS B, LAGERGARD T, GUNNARSSON E, TARANGER J: Determination of pertactin IgG antibodies for the diagnosis of pertussis. Clin. Microbiol. Infect. (2003) 9(7):585-589.
62. DE MELKER HE, SCHELLEKENS JF, NEPPELENBROEK SE et al.: Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg. Infect. Dis. (2000) 6(4):348-357.
63. VAN BOVEN M, DE MELKER HE, SCHELLEKENS JF, KRETZSCHMAR M: A model based evaluation of the 1996-7 pertussis epidemic in the Netherlands. Epidemiol. Infect. (2001) 127:73-85.
64. MOOI FR, VAN OIRSCHOT H, HEUVELMAN K, VAN DER HEIDE HG, GAASTRA W, WILLEMS RJ: Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence of vaccine-driven evolution. Infect. Immun. (1998) 66:670-675.
65. MOOI FR, HE Q, VAN OIRSCHOT H, MERTSOLA J: Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. (1999) 67:3133-3134.
66. MASTRANTONIO P, SPIGAGLIA P, VAN OIRSCHOT H et al.: Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology (1999) 45:2069-2075.
67. DECRETO DEL PRESIDENTE DELLA REPUBBLICA: 7 novembre 2001, n.464. Regolamento recante modalità di esecuzione delle rivaccinazioni antitetaniche, a norma dell'articolo 93, comma 2, della legge 23 dicembre 2000, n.388.
68. PICHICHERO ME, TREANOR J: Economic impact of pertussis. Arch. Pediatr. Adolesc. Med. (1997) 151(1):35-40.
69. EDMUNDS WJ, BRISSON M, MELEGARO A, GAY NJ: The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine (2002) 20:1316-1330.